Lawarence Recht
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lawarence Recht as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06855628 · Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)Stanford University · completed · Glioma, GBM · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Enhanced Deuterium Metabolic Imaging (DMI) of Metabolic Reprogramming in Brain TumorsR01CA277832 · NCI · STANFORD UNIVERSITY · PI Daniel M Spielman · fiscal years 2023 to 2026Named on NCT06855628
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 09:22 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.Lancet Oncol · 2017953 citationsRCR 30.9
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.Neuro Oncol · 2015345 citationsRCR 10.5
- First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.J Neurooncol · 2018139 citationsRCR 6.3
- 125 citationsRCR 4.2
- Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.Clin Cancer Res · 201991 citationsRCR 2.9
- A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).J Neurooncol · 201451 citationsRCR 1.7
- A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.Neuro Oncol · 202046 citationsRCR 2.3
- Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay.Semin Oncol · 200920 citationsRCR 0.5
- Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant Temozolomide.Pract Radiat Oncol · 202320 citationsRCR 2.7
- Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.J Neurooncol · 201515 citationsRCR 0.5